Ratings Bolt Biotherapeutics, Inc.

Equities

BOLT

US0977021049

Market Closed - Nasdaq Other stock markets 01:30:00 2024-07-03 pm EDT			5-day change	1st Jan Change
0.7375 ^USD	+0.34%		-0.38%	-34.15%

May. 20	Bolt Biotherapeutics, Inc. Announces Management Changes	CI
May. 20	Bolt Biotherapeutics, Inc. Announces Chief Executive Officer Changes	CI

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
The company appears to be poorly valued given its net asset value.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the past twelve months, EPS forecast has been revised upwards.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Over the past four months, analysts' average price target has been revised downwards significantly.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' opinions have been revised negatively.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
BOLT BIOTHERAPEUTICS, INC.	-34.15%	28.02M	-
VERTEX PHARMACEUTICALS INCORPORATED	+15.69%	122B	B+
REGENERON PHARMACEUTICALS, INC.	+16.62%	113B	B+
ARGENX SE	+17.55%	26.22B	B
BIONTECH SE	-24.32%	19.01B	B+
GENMAB A/S	-19.14%	15.71B	A-
BEIGENE, LTD.	-18.01%	15.22B	B
WUXI APPTEC CO., LTD.	-46.81%	14.72B	A-
SAREPTA THERAPEUTICS, INC.	+59.08%	14.58B	C+
NEUROCRINE BIOSCIENCES, INC.	+4.84%	13.84B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes